news today after the meeting, page-23

29 October, 2008
Company Announcement
Ropren® Pricing and Russian Distribution Update
The Directors of Solagran Limited are pleased to inform the market of some key outcomes
from Mr Charles Pellegrino’s recent trip to Russia.
The price per course of USD1,125 for Ropren® in Russia that was signalled in the
Chairman’s letter in the 2008 Annual Report has been confirmed. Written agreements with
nine hospitals in St Petersburg for supply at that price are currently being finalised. A
number of important initiatives in relation to Ropren® distribution throughout the remainder of
Russia are close to finalisation and details will be revealed when documentation is complete.
Discussions were held with opinion leading clinicians including Prof. Inna Gavrisheva, Prof.
Yelena Lapteva and Dr Vladimir Agishev, as well as the head of a major pharmacy network,
who will each play an important role in Solagran’s Ropren® distribution strategy.
During these discussions, Professor Lapteva revealed that she had already been
approached by medical authorities in Slovakia seeking supply of Ropren® in that country.
Prof. Gavrisheva, co-ordinated the Ropren® clinical trials in 2003-04. Based on her
observations during those trials, she urged Mr Pellegrino to communicate to the Solagran
Board her strong recommendation that the company undertake clinical trials with Ropren® in
the treatment of AIDS patients at The Centre for Infectious Diseases and AIDS in St
Petersburg.
Mr Pellegrino has signed off on a production plan at the Tomsk facility which is on track and
already producing 15kg of Bioeffective® R per month at purity sufficient for pharmaceutical
production.
Mr Pellegrino was also able to meet with officials from the Special Economic Zone authority.
He was most impressed with the progress of construction of the shared facilities within the
zone, and was given formal documentation confirming Solagran’s participation.
Peter Stedwell